What is BAKX Therapeutics?
Headquartered in New York City, New York, BAKX Therapeutics is a biopharmaceutical company dedicated to advancing the potential of mitochondrial apoptosis pathways. The company's core mission is to create safer and more effective therapeutic solutions, addressing critical unmet needs in patient care. This focus positions BAKX Therapeutics at the forefront of innovative drug development within the competitive life sciences sector.
How much funding has BAKX Therapeutics raised?
BAKX Therapeutics has raised a total of $25M across 1 funding round:
Series A
$25M
Series A (2021): $25M with participation from AB Magnitude Ventures Group, Sherpa Healthcare Partners, and Ipsen Pharma
Key Investors in BAKX Therapeutics
Sherpa Healthcare Partners
Sherpa Healthcare Partners is an investor in the biotechnology and healthcare sectors, likely focusing on companies with innovative therapeutic approaches.
Ipsen Pharma
Founded in 1929 and headquartered in Boulogne, France, Ipsen Pharma is a global biopharmaceutical group focused on specialty care. The Group develops and commercializes medicines in therapeutic areas including oncology, neuroscience, and rare diseases.
AB Magnitude Ventures Group
AB Magnitude Ventures Group is an investment entity that has participated in this significant funding round for BAKX Therapeutics.
What's next for BAKX Therapeutics?
The substantial enterprise-level funding and strategic investment indicate a pivotal growth phase for BAKX Therapeutics. This capital infusion is expected to accelerate the company's research and development pipeline, potentially enabling further clinical trials and the expansion of its therapeutic offerings. The strategic nature of the recent financing suggests strong alignment with key industry players, paving the way for future collaborations and market penetration.
See full BAKX Therapeutics company page
